Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

The mechanisms behind the evolution of complex genomic amplifications in cancer have
remained largely unclear. Using whole-genome sequencing data of the pediatric tumor …

The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …

Despite the development of targeted therapy, drug resistance remains a primary hindrance
to curative treatment of various cancers. Among several novel approaches to overcome drug …

Extrachromosomal DNA (ecDNA) is a common mode of oncogene amplification but is
challenging to analyze. Here, we adapt CRISPR-CATCH, in vitro CRISPR-Cas9 treatment …

Extrachromosomal DNA (ecDNA) is prevalent in human cancers and mediates high
expression of oncogenes through gene amplification and altered gene regulation. Gene …

Oncogenic extrachromosomal DNA elements (ecDNA) play an important role in tumor
evolution, but our understanding of ecDNA biology is limited. We determined the distribution …

Non-genetic mechanisms have recently emerged as important drivers of anticancer drug
resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more …

The human papillomavirus (HPV) genome is integrated into host DNA in most HPV-positive
cancers, but the consequences for chromosomal integrity are unknown. Continuous long …